Fairvalue-Calculator Fairvalue-Calculator
EN DE

LabTurbo Biotech Corporation (7725) Fair Value & Analysis

Healthcare · TW · Market cap 1.1B TWD

Price22.60 TWD
Fair Value5.41 TWD
Upside-76.1%
Quality88/100
Evidence: Medium Range 4.06 TWD – 6.76 TWD

Fair value as of: Jun 24, 2026

Analysis

LabTurbo Biotech Corporation (7725) currently trades at 22.60 TWD, while our model-based Fair Value estimate is 5.41 TWD — implying the stock looks roughly 76.1% overvalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

LabTurbo Biotech Corporation engages in the research, manufacture, and sale of gene detection systems and kits in Taiwan, the United States, the Czech Republic, Spain, France, Israel, Singapore, the Philippines, and Malaysia. It serves hospitals. The company was founded in 2000 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is LabTurbo Biotech Corporation (7725) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 5.41 TWD versus a price of 22.60 TWD — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 7725?
Our 21-model fair value for LabTurbo Biotech Corporation is 5.41 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 22.60 TWD.
What is the quality score of 7725?
LabTurbo Biotech Corporation has a Quality Score of 88/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.